Here are the 10-K annual reports from Coeptis Therapeutics Holdings Inc. (COEP) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow COEP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full COEP filings page.
Coeptis Therapeutics Holdings, Inc. files its annual report describing a small, development‑stage biopharmaceutical and technology company with no approved drugs, minimal revenue and a focus on cell therapies and AI‑driven marketing software. The biopharma division is advancing preclinical platforms including CD38‑GEAR‑NK, CD38‑Diagnostic, the SNAP‑CAR universal cell therapy platform and allogeneic NK programs licensed from Deverra.
In 2025 Coeptis recorded a net loss of $12,277,192, bringing its accumulated deficit to $109,953,728, and its auditors raise substantial doubt about its ability to continue as a going concern. The company reports only six employees and expects to continue incurring losses while it funds R&D and looks for partners.
Strategically, Coeptis acquired the NexGenAI Affiliates Network marketing automation platform and agreed in April 2025 to spin out its biotechnology assets to shareholders while merging with Z Squared, Inc., with closing expected in the second quarter of 2026. The company highlights significant regulatory, financing, competition and Nasdaq listing risks and operates as an emerging growth company using reduced reporting requirements.